Familial Cancer Registry and DNA Bank

Sponsor
National University Hospital, Singapore (Other)
Overall Status
Unknown status
CT.gov ID
NCT02083224
Collaborator
(none)
2,000
1

Study Details

Study Description

Brief Summary

Clinical cancer genetics is an emerging new field in medical oncology, and has been incorporated into routine oncology practice in many leading medical institutions in North America and Europe. Cancer genetics is the study of genetic factors contributing to carcinogenesis. In the last 5-10 years, genes responsible for various well-defined hereditary cancer syndromes have been cloned. These include the BRCAJ/2 genes in hereditary breast and ovarian cancer syndrome, the A4PC gene in Familial Adenomatous Polyposis, and the mismatch repair genes (hMLH1, hMSH2, hPMS1, hPMS2, hMSH6) in hereditary non-polyposis colorectal cancer (HNPCC). One of the goals of a clinical cancer genetics service is to identify families at risk for hereditary cancer syndromes, provide genetic counseling, and offer genetic testing when appropriate. The identification of causative genes in hereditary cancer syndromes together with the advent of genetic testing is starting to have an impact on clinical management. The ability to identify a gene mutation in a cancer family allows predictive testing, stratifying at-risk family members into carriers who will benefit from aggressive surveillance and/or preventive options, and non-carriers who may be spared unnecessary surveillance. Appropriate use of genetic testing will ultimately result in medical cost reduction.

The investigators hypothesize that the clinical characteristics and genetic factors contributing to hereditary cancer in the Singaporean Asian population are distinct from those described for Western patients.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Familial Cancer Registry and DNA Bank
    Study Start Date :
    Jan 1, 2000
    Anticipated Primary Completion Date :
    Dec 1, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    Cancer patients

    Outcome Measures

    Primary Outcome Measures

    1. Change in genetics testing method [2 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Any individual with very early onset cancer (eg diagnosed before age 40).

    • Any family with three or more first- or second-degree relatives with the same cancer

    • Any individual with two or more different primary cancers

    • Any family that fulfils diagnostic criteria for known hereditary cancer syndromes

    Exclusion Criteria:

    Nil

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National University Hospital Singapore Singapore 119074

    Sponsors and Collaborators

    • National University Hospital, Singapore

    Investigators

    • Principal Investigator: Soo Chin Lee, MBBS, MRCP, National University Hospital, Singapore

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Haematology-Oncology, Lee Soo Chin, National University Hospital, Singapore
    ClinicalTrials.gov Identifier:
    NCT02083224
    Other Study ID Numbers:
    • 2000/00511
    First Posted:
    Mar 11, 2014
    Last Update Posted:
    Mar 11, 2014
    Last Verified:
    Mar 1, 2014

    Study Results

    No Results Posted as of Mar 11, 2014